Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
Status:
Completed
Trial end date:
2017-01-27
Target enrollment:
Participant gender:
Summary
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and
Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab
in combination with MEDI4736 in Japanese Patients with Advanced Solid Malignancies, and when
given as a monotherapy of tremelimumab in Second- or Third-line Treatment of Japanese
Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma